HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors
Clinical trial NCT04965220 · UNKNOWN
Trial details
- NCT number
- NCT04965220
- Sponsor
- Shanghai Henlius Biotech
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-05
- Primary completion
- 2024-06-30
- Enrollment
- 220
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.